|
|
Research Study Trials Current/Prospective
DEVICE TRIALS
- MEDTRONIC ATP - ATP in Fast VT Study
- CARS Sweet Tip - Study to show that the pacing thresholds of the
Sweet Tip RX is different than that of other market-released steroid-eluting
positive-fixation pacing leads.
- CARS - AICD- Comparison of Dual and Single chamber therapy responsiveness
using the Guidant Ventak AICD family.
- ST. Jude AutoCapturePacing Systems feature when the system is utilizing
a current U.S. market approved lead other than the Passive Plus
DX and Tendril DX.
- RID-AF Reduced Incidence and Duration (Burden) of AF/AT with the
Jewel AF/GEM III AT-Study to determine whether patients with atrial
tachyarrhythmia prevention and termination therapies programmed
ON spend less overall time in AF/AT than patients with atrial tachyarrhythmia
prevention therapies turned OFF.
- Silent Atrial Fibrillation Detection with Stored EGMS (SAFE) - Study
that will investigate the percentage of patients with sick sinus
syndrome that develop AD after pacemaker implantation. Investigating
EGM capabilities of dual chamber Guidant device.
- Synergistic Effects of Risk Factors for Sudden Cardiac Death (SERF)
- Study to evaluate simultaneous effects of common risk factors
for sudden cardiac death incidence in newly implanted ICD patients.
DRUG TRIALS
- Merit HF - Randomized intervention trial in Heart Failure evaluating
the efficacy of a beta blocker.
- Prince Study - Study to evaluate the effects of 40 mg oral pravastatin
daily on plasma concentrations of hs-CRP over a 24 week treatment.
Random assigned to pravastatin or to placebo.
- ALIVE - AzimilidePost Infarct Survival Evaluation Trial. Double
blind placebo controlled parallel designed study to determine the
effect of 75 or 100 mg orally administered Azimilide dihydrochloride
versus placebo on the survival in recent post myocardial infarction
patients at risk of sudden death.
- BRAVO- Blockage of the GPIIB/IIIA receptor to avoid vascular occlusion.
To compare the incidence of clinical events in patients receiving
lotrafiban or placebo when combined with ASA for at least 6 months
and up to two years.
- MAGIC - Double-blind placebo controlled trial that will randomize
acute MI patients at high risk of mortality to either a magnesium
or placebo infusion started within 6 hours or symptom onset and
administration over 24 hours.
- ALLHAT - Antihypertensive and lipid lowering treatment to prevent
heart attack trial.
- IMPACT - A 12-week, open-label study to examine patient compliance
and incidence of liver function abnormalities with Advicor.
- SYNERGY Study - Prospective, randomized, open-label, multi-center
study in high risk patients presenting with non-ST segment elevation
acute coronary syndromes, including unstable angina and non-ST elevation
MI managed with and intended early invasive treatment strategy.
Patients will be randomized to receive UFH or enoxaparin and will
receive concomitant anti-platelet and anti-ischemic therapy.
INTERVENTION/MEDICATION TRIAL
- OAT - opening an occluded infarct artery within 3-28 days post
acute MI. Subjects are randomized to conventional therapy or conventional
plus PTCA/stent.
REGISTRIES
- MEDTRONIC AVE Stent- To determine the long term effectiveness of
Medtronic AVE S540 coronary stents in native coronary lesions.
- COHERE - To collect clinically pertinent outcome data (e.g., mortality,
need for hospitalization, use of concomitant medications, patient
global assessment, NYHA class in patients with heart failure receiving
Coreg.
|
|
